MedWatch

Analyst on Ambu report: Mixed results but still thumbs-down

Senior Equity Analyst at Sydbank Søren Løntoft Hansen wasn’t particularly impressed by the figures presented in Ambu’s first quarterly report on Tuesday, although certain areas fared better than feared.

Photo: Ambu / PR

On Tuesday, Ambu publicized the first quarterly report for the staggered accounting period 2021/2022 – and while it was a mixed bag, it was mostly negative, concludes Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.

”If any positives are taken from the report, it is a better-than-expected net result. The gross margin is taking a considerable step back, but it is smaller than feared,” says Løntoft Hansen, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs